ArticleEuropean heart journal supplements : journal of the European Society of Cardiology2021
Surprises in cardiology: efficacy of gliflozines in heart failure even in the absence of diabetes.
Article in European heart journal supplements : journal of the European Society of Cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Empagliflozin Improves Learning and Memory Deficits in Streptozotocin-Induced Hyperglycemic Male Wistar Rats.Journal of experimental pharmacology · 2026Article
- New Insights into Uric Acid Metabolism in the Pathophysiology of Ischaemic Heart Disease.European cardiology · 2025Review
- Assessment of Gliflozins prescribing pattern in a United Arab Emirates tertiary-level care hospital.Frontiers in pharmacology · 2025Article
- Associations between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and hyperuricemia: a cross-sectional study.Lipids in health and disease · 2024Article
- Association of Body Mass Index with Outcomes in Patients with Heart Failure with Reduced Ejection Fraction (HFrEF).Nutrients · 2024Article
- The Ketogenic Effect of SGLT-2 Inhibitors-Beneficial or Harmful?Journal of cardiovascular development and disease · 2023Review
- Sizing SGLT2 Inhibitors Up: From a Molecular to a Morpho-Functional Point of View.International journal of molecular sciences · 2023Review
- Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors.International journal of molecular sciences · 2023Review
- Myocardial Cell Preservation from Potential Cardiotoxic Drugs: The Role of Nanotechnologies.Pharmaceutics · 2022Review
- The overall benefits of empagliflozin treatment in adult siblings with glycogen storage disease type Ib: one year experience.Archives of medical science : AMS · 2022Article
- The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients.Journal of personalized medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is now well-established that the therapy of type II diabetes mellitus has undergone a radical change in the past 15 years: countless innovative drugs, such as SGLT2I, able to guarantee an optimization of glycaemic control without causing hypoglycaemia, today represent real therapeutic cornerstones not only for the intrinsic ability of these molecules to ensure better glycaemic control but also for the effects they exert on the cardiovascular system. Several pioneering clinical trials, such as EMPA-REG, CANVAS, and DECLARE-TIMI-58, have demonstrated clear benefits of empagliflozin, canagliflozin, and dapagliflozin, respectively, in reducing cardiovascular risk and diabetes-associated macrovascular complications in the diabetic population. The promising results that emerged from these trials represent the spark that triggered a series of studies aimed at evaluating the efficacy of gliflozines in the treatment of patients with heart failure even in the absence of diabetes. Preliminary results confirm the efficacy of SGLT2I in the treatment of this population, representing a real therapeutic revolution.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.